Tuesday's Health Winners & Losers
Health stocks came off the holiday weekend with modest gains, though Onyx Pharmaceuticals (ONXX) was left choking on a clinical trial news.
Onyx and partner Bayer AG said Tuesday that they halted a late-stage trial of their drug Nexavar in lung cancer patients after an independent monitoring board concluded that the study had no chance to succeed. Onyx also said on a conference call that it is unable to forecast a profit for 2008. Shares shed $10.69, or 24%, to $34.25.
Elsewhere, Medivation (MDVN) said Tuesday its 2007 loss more than doubled due to an increase in operating expenses, though the results were better than Wall Street expectations. The biopharmaceutical company reported a loss of $31.7 million, or $1.14 a share, widened from a loss of $15.4 million, or 63 cents a share, in 2006. Analysts anticipated a loss of $1.17 a share.
Shares of Medivation rose 76 cents, or 4.4%, to $17.86 on less-than-average volume.Onyx and Medivation are both components of the Nasdaq biotechnology index, which was up 1.65, or 0.2%, to 797.12. Elsewhere, UBS analyst Annabel Samimy downgraded Pharmasset (VRUS) to neutral from buy, but raised her price target to $23 from $17 a share. She believes that the value of the company's hepatitis B and C drugs, clevudine and R7128, is now reflected in the stock price. Shares of Pharmasset fell $1.53, or 7.1%, at $19.97. Among upgrades, WR Hambrecht raised Watson Pharmaceuticals (WPI) to buy from hold and BMO Capital Markets upgraded UnitedHealth (UNH) to outperform from market perform. Watson tacked on 45 cents, or 1.7%, to 28.40, and UnitedHealth shares added 55 cents, or 1.1%, at 48.28. Also, Thomas Weisel upgraded Cephalon (CEPH) to overweight from market-weight with a $77 price target. Shares advanced 97 cents, or 1.6%, at $61.59. Separately, Cephalon said the Food and Drug Administration accepted its new drug application for Treanda for injection to treat of patients with indolent B-cell non-Hodgkin's lymphoma who've progressed during or following standard treatment. An FDA decision is expected by Oct. 31. And last, on the falling end, Given Imaging (GIVN) said late Monday that the FDA issued it a "not substantially equivalent" letter that indicated the agency will not approve the company's PillCam Colon imaging device. Given Imaging, which makes tiny diagnostic cameras, said the development isn't likely to affect 2008 revenue. The company said it is evaluating its options to bring PillCam Colon to the U.S. market as quickly as possible. Shares fell $2.15, or 13.9%, to $13.30. Given Imaging is 18.3% held by Israeli company Elron Electronic Industries (ELRN). Elron was trading down $1.17, or 10.9%, at $9.53.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV